Literature DB >> 24150746

Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria.

Hernán Maldonado Ficco1, Gustavo Citera, José Antonio Maldonado Cocco.   

Abstract

The aim of this study is to determine the prevalence of psoriatic arthritis (PsA) according to CASPAR criteria, ASAS peripheral and axial SpA criteria, and New York criteria for AS. The first 100 patients consecutively attending a psoriasis dermatology clinic were assessed. Demographic and clinical data were collected; all patients were questioned and examined for joint manifestations. Rheumatoid factor and radiographies of hands, feet, cervical spine, and pelvis for sacroiliac joints were obtained. X-rays were read independently by two experienced observers in blind fashion. Patients with objective joint manifestations, both axial and peripheral, were evaluated for fulfillment of CASPAR, ASAS peripheral and axial, and New York criteria. Median age 48 years; 93 % of patients had psoriasis vulgaris and 56 % nail involvement. Seventeen patients had peripheral arthritis as follows: nine mono/oligoarticular and eight polyarthritis. Median arthritis duration was 8 years. Seventeen percent of patients fulfilled CASPAR and ASAS peripheral criteria, 6 % New York, and 5 % ASAS axial criteria. Patients who met CASPAR criteria showed a significantly higher psoriasis duration compared to those without arthritis (M 16 vs. 10 years, p = 0.02), and a higher frequency of nail involvement (88.2 vs. 49.4 %, p = 0.003). Five patients (29.4 %) fulfilled ASAS axial criteria; all of them had peripheral involvement as follows: mono/oligoarticular in three patients and polyarticular in two. Patients with peripheral and axial involvement presented a significantly higher frequency of erythrodermic psoriasis compared to the other patients (35.3 vs. 1.2 %, p = 0.0006 and 80 vs. 16.7 %, p = 0.02). Prevalence of PsA, for CASPAR and ASAS peripheral criteria, was of 17 %. Five percent of patients met ASAS axial criteria, while 6 % met New York criteria. Worth noting, few patients without signs or symptoms of arthritis had radiological changes, both axial and peripheral, precluding a proper classification.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24150746     DOI: 10.1007/s10067-013-2412-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

2.  Incidence and prevalence of psoriatic arthritis: a systematic review.

Authors:  Yannis Alamanos; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

Review 3.  Psoriatic arthritis.

Authors:  D D Gladman
Journal:  Rheum Dis Clin North Am       Date:  1998-11       Impact factor: 2.670

Review 4.  Psoriatic arthritis.

Authors:  J M Moll; V Wright
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

5.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

6.  Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society.

Authors:  S Hukuda; M Minami; T Saito; H Mitsui; N Matsui; Y Komatsubara; H Makino; T Shibata; M Shingu; T Sakou; K Shichikawa
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

7.  In the era of nephelometry, latex agglutination is still good enough to detect rheumatoid factor.

Authors:  Venugopalan Anuradha; Arvind Chopra
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

8.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

Review 9.  The early phase of psoriatic arthritis.

Authors:  Dennis McGonagle; Zoe Ash; Laura Dickie; Michael McDermott; Sibel Zehra Aydin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

10.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

Authors:  M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

View more
  7 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting.

Authors:  Neal Bhatia; Andrew Blauvelt; Marc Brown; Whitney High; Craig T Leonardi; Ted Rosen; Linda Stein Gold; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

Review 3.  Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.

Authors:  Carolyn Jean Chua-Aguilera; Burkhard Möller; Nikhil Yawalkar
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

4.  Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.

Authors:  Enrique Roberto Soriano; Federico Zazzetti; Ivanio Alves Pereira; José Maldonado Cocco; Valderilio Feijó Azevedo; Generoso Guerra; Wilson Bautista-Molano; Julio César Casasola; David Vega Morales; Diana Rocío Gil; Steve Lobosco; Fabio Lawson
Journal:  Clin Rheumatol       Date:  2020-01-28       Impact factor: 2.980

5.  Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.

Authors:  Vibeke Strand; Elaine Husni; Jenny Griffith; Zheng-Yi Zhou; James Signorovitch; Arijit Ganguli
Journal:  Rheumatol Ther       Date:  2016-09-15

6.  Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center.

Authors:  S Santilli; D R Kast; I Grozdev; L Cao; R L Feig; J B Golden; S M Debanne; R C Gilkeson; C E Orringer; T S McCormick; N L Ward; K D Cooper; N J Korman
Journal:  J Transl Med       Date:  2016-07-22       Impact factor: 5.531

7.  Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing.

Authors:  Yu-Jih Su
Journal:  Clin Rheumatol       Date:  2020-05-28       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.